Immatics Stock (NASDAQ:IMTX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$9.33

52W Range

$7.98 - $13.77

50D Avg

$10.81

200D Avg

$11.39

Market Cap

$1.12B

Avg Vol (3M)

$502.20K

Beta

0.75

Div Yield

-

IMTX Company Profile


Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

DE

Employees

542

IPO Date

Dec 12, 2018

Website

IMTX Performance


IMTX Financial Summary


Dec 23Dec 22Dec 21
Revenue€54.00M€172.83M€34.76M
Operating Income€-101.72M€29.95M€-86.29M
Net Income€-96.99M€37.51M€-95.06M
EBITDA€-80.65M€46.34M€-75.36M
Basic EPS€-1.20€0.56€-1.51
Diluted EPS€-1.20€0.55€-1.51

Fiscal year ends in Dec 23 | Currency in EUR

Peer Comparison


TickerCompany
BCABBioAtla, Inc.
MRUSMerus N.V.
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
INBXInhibrx Biosciences, Inc.
FENCFennec Pharmaceuticals Inc.
REPLReplimune Group, Inc.
ALXOALX Oncology Holdings Inc.
SNDXSyndax Pharmaceuticals, Inc.
LYELLyell Immunopharma, Inc.
JANXJanux Therapeutics, Inc.
KRONKronos Bio, Inc.
KROSKeros Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.
CRNXCrinetics Pharmaceuticals, Inc.